Generic Zolinza Availability
Last updated on May 7, 2025.
Zolinza is a brand name of vorinostat, approved by the FDA in the following formulation(s):
ZOLINZA (vorinostat - capsule;oral)
-
Manufacturer: MSD SUB MERCK
Approval date: October 6, 2006
Strength(s): 100MG [RLD]
Is there a generic version of Zolinza available?
No. There is currently no therapeutically equivalent version of Zolinza available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zolinza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods of treating cancer with HDAC inhibitors
Patent 7,399,787
Issued: July 15, 2008
Inventor(s): Chiao; Judy H. et al.
Assignee(s): Merck HDAC Research, LLC (Boston, MA)The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Patent expiration dates:
- February 9, 2025✓
- February 9, 2025
-
Polymorphs of suberoylanilide hydroxamic acid
Patent 7,456,219
Issued: November 25, 2008
Inventor(s): Miller; Thomas A. et al.
Assignee(s): Merck HDAC Research, LLC (Boston, MA)The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
Patent expiration dates:
- March 11, 2027✓
- March 11, 2027
-
Formulations of suberoylanilide hydroxamic acid and methods for producing the same
Patent 8,093,295
Issued: January 10, 2012
Inventor(s): Wong Jeannie Chow & Cohen Benjamin Max & Cote Aaron S. & Dienemann Erik A. & Gallagher Kimberly & Ikeda Craig & Moser Justin & Rajniak Pavol & Reed Robert A. & Sell Brian & Starbuck Cindy & Tung Hsien-Hsin & Wang Qingxi & Capodanno Vincent R.
Assignee(s): Merck Sharp & Dohme Corp.The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
Patent expiration dates:
- May 16, 2026✓
- May 16, 2026
-
Formulations of suberoylanilide hydroxamic acid and methods for producing same
Patent 8,450,372
Issued: May 28, 2013
Inventor(s): Wong Jeannie Chow & Cote Aaron S. & Dienemann Erik A. & Gallagher Kimberly & Ikeda Craig & Moser Justin & Rajniak Pavol & Reed Robert A. & Starbuck Cindy & Tung Hsien-Hsin & Wang Qingxi & Cohen Benjamin Max & Capodanno Vincent R. & Sell Brian & Miller Thomas A.
Assignee(s): Merck Sharp & Dohme Corp.The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
Patent expiration dates:
- March 18, 2028✓
- March 18, 2028
More about Zolinza (vorinostat)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: histone deacetylase inhibitors
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Actimmune
Actimmune is used for chronic granulomatous disease, cutaneous t-cell lymphoma, idiopathic ...
Istodax
Istodax is used to treat T-cell lymphoma affecting the skin. Learn about side effects, interactions ...
Lymphir
Lymphir (denileukin diftitox-cxdl) is an injectable targeted cancer treatment that may be used to ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
